According to preclinical research published in Cell, researchers with City of Hope discovered that a type of human immune cells known to be important for allergy and other immune responses—human type 2 innate lymphoid cells, or ILC2s—can also attack cancer.
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations.
